Plasma adiponectin concentration is associated with ambulatory daytime systolic blood pressure but not with the dipping status

Journal of Human Hypertension

Volumn 24, Issue 8, 2010, Pages 545-551

  Vasunta, R L ^a   Kesaniemi Y A ^a   Ukkola, O ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

adiponectin; ambulatory blood pressure; dipping pattern

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; INDEPENDENT VARIABLE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; OSCILLOMETRY; PROTEIN BLOOD LEVEL; SEX RATIO; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; ADRENERGIC SYSTEM; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; CIRCADIAN RHYTHM; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ADIPONECTIN; ADULT; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RISK FACTORS; SEX DISTRIBUTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 77954818459     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.98     Document Type: Article

References (40)

1. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005; 6: 7-14.
2. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
3. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88: 3236-3240.
4. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N et al. Association of hypoadi-ponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
5. Guerre-Millo M. Adiponectin: an update (review). Diabetes Metab 2008; 34: 12-18.
6. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
7. Santaniemi M, Kesaniemi YA, Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 2006; 155: 745-750. (Pubitemid 44857499)
8. Cesari M, Pessina A, Zanchetta M, De Toni R, Avogaro A, Pedon L et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. J Intern Med 2006; 260: 474-483.
9. Chow W, Cheung B, Tso A, Xu A, Wat N, Fong C et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007; 49: 1455-1461.
10. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Sakamoto T et al. Hypoadiponectinemia is associated with impaired glucose tolerance and coronary artery disease in non-diabetic men. Circ J 2007; 71: 1703-1709.
11. Tsioufis C, Dimitriadis K, Selima M, Thomopoulos C, Mihas C, Skiadas I et al. Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients. Eur Heart J2007; 28: 1162-1169.
12. Sung S, Chuang S, Sheu W, Lee W, Chu P, Chen C. Adiponectin, but not leptin or high-sensitivity C-reactive protein, is associated with blood pressure independently of general and abdominal adiposity. Hypertens Res 2008; 31: 633-640.
13. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 16: 72-75.
14. Huang K, Chen C, Chuang L, Ho S, Tai T, Yang W. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab 2003; 88: 4130-4134.
15. Imai Y, Satoh H, Nagai K, Sakuma M, Sakuma H, Minami N et al. Characteristics of a community-based distribution of home blood pressure in Ohasama in northern Japan. J Hypertens 1993; 11(12): 1441-1449. (Pubitemid 24008493)
16. Imai Y, Ohkubo T. Ambulatory blood pressure normality: experience in the Ohasama study. Blood Press Monit 1998; 3(3): 185-188.
17. Verdecchia P. Ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35: 844-851.
18. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet 1988; 2: 397.
19. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536.
20. Verdecchia P, Schillaci G, Zampi I, Gatteschi C, Battistelli M, Bartocchini C et al. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation 1993; 88: 986-992.
21. Timio M, Venanzi S, Lolli S, Lippi C, Verdura E, Guerrini E et al. Daytime blood pressure and progression of renal insufficiency. High Blood Pressure Cardiovasc Prev 1994; 3: 39-44.
22. Fagard RH, Staessen JA, Thijs L. The relationships between left ventricular mass and daytime and daytime blood pressure: a meta-analysis of comparative studies. JHypertens 1995; 13: 823-829.
23. Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000; 36: 894-900.
24. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006; 354(22): 2368-2374.
25. Tsioufis C, Antoniadis D, Stefanadis C, Tzioumis K, Pitsavos C, Kallikazaros I et al. Relationships between new risk factors and circadian blood pressure variation in untreated subjects with essential hypertension. Am JHypertens 2002; 15(7 Pt 1): 600-604.
26. Della Mea P, Lupia M, Bandolin V, Guzzon S, Sonino N, Vettor R et al. Adiponectin, insulin resistance, and left ventricular structure in dipper and non-dipper essential hypertensive patients. Am JHypertens 2005; 18(1): 30-35.
27. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesaniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999; 245(2): 163-174.
28. Kauma H, Savolainen MJ, Heikkila R, Rantala AO, Lilja M, Reunanen A et al. Sex difference in the regulation of plasma high density lipoprotein cholesterol by genetic and environmental factors. Hum Genet 1996; 97(2): 156-162.
29. Poykko SM, Ukkola O, Kauma H, Kellokoski E, Horkko S, Kesaniemi YA. The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes. Diabetologia 2005; 48(2): 309-316.
30. Huikuri HV, Ylitalo A, Pikkujamsa SM, Ikaheimo MJ, Airaksinen KE, Rantala AO et al. Heart rate variability in systemic hypertension. Am J Cardiol 1996; 77(12): 1073-1077.
31. O'Brien E, Coats A, Owens P, Petrie J, Padfield P, Littler WA et al. Use and, interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ2000; 320: 1128-1134.
32. Ylitalo A. Cardiovascular autonomic regulation in systemic hypertension. Acta Universitatis Ouluensis Medica, D 519 1999: 37 ISBN 951-42-5211-X. ISSN 0355-3221.
33. Matsuda M, Shimomura I, Sata M, Arita Y, Nishida M, Maeda N et al. Role of adiponectin in preventing vascular stenosis: the missing link of adipo-vascular axis. JBiol Chem 2002; 277(40): 37487-37491.
34. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponec- tin actions in the cardiovascular system. Cardiovasc Res 2007; 74(1): 11-18.
35. Zhu W, Cheng KY, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci 2008; 114: 361-374.
36. Imai J, Katagiri H, Yamada T, Ishigaki Y, Ogihara T, Uno K et al. Cold exposure suppresses serum adipo-nectin levels through sympathetic nerve activation in mice. Obesity (Silver Spring) 2006; 14: 1132-1141.
37. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008; 51(1): 8-14.
38. Strandberg TE, Pitkala K. What is the most important component of blood pressure: systolic, diastolic or pulse pressure? Curr Opin Nephrol Hypertens 2003; 12(3): 293-297.
39. Lam KS, Xu A. Adiponectin: protection of the endothelium. Curr Diab Rep 2005; 5: 254-259.
40. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.